NDAINJECTIONINJECTABLE
Approved
Mar 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER (cefoxitin sodium) by B. Braun is 12. Approved for lower respiratory tract infections, including pneumonia, lung abscess and 33 more indications. First approved in 2006.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Cefoxitin sodium in dextrose duplex container is a second-generation cephalosporin antibiotic administered intravenously for treatment of bacterial infections across respiratory, urinary, intra-abdominal, gynecological, and surgical prophylaxis indications. The drug acts as a bactericidal agent by inhibiting bacterial cell wall synthesis and maintains activity against beta-lactamase-producing gram-positive and gram-negative organisms. It is supplied in a ready-to-use duplex container format combining cefoxitin with dextrose for convenient hospital administration.
LOE Approaching
Product is in late-stage commercial lifecycle with approaching loss of exclusivity, indicating consolidation of smaller brand team and transition focus toward generic competition management.
Mechanism of Action
12.1 Mechanism of Action Cefoxitin is an antibacterial drug [ ] . 12.2 Pharmacodynamics The pharmacodynamic properties of cefoxitin are unknown. 12.3 Pharmacokinetics Absorption Following an intravenous dose of 1 gram, serum concentrations were 110 mcg/mL at 5 minutes, declining to less than 1…
Worked on CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER at B. Braun? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.